Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | Journal of Biomedical Science

Fig. 2

From: Expanding applications of allogeneic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery

Fig. 2

Overview of the various virus safety measures in place in the blood transfusion and industrial plasma fractionation industry, and supervised by regulatory authorities, as potential models to be implemented for optimal virus safety margin of pooled human platelet lysates and platelet extracellular vesicles for clinical applications. p-EV platelet extracellular vesicles, HPL human platelet lysate, NAT nucleic acid testing, PC platelet concentrate

Back to article page

Journal of Biomedical Science

ISSN: 1423-0127